相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
Carlo Visco et al.
HAEMATOLOGICA (2013)
Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Massimo D’Amico et al.
Recent Patents on Anti-Cancer Drug Discovery (2013)
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
Wendy Cuccuini et al.
BLOOD (2012)
Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
Nalan Akyurek et al.
CANCER (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
C. Visco et al.
LEUKEMIA (2012)
Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
Michael J. Kluk et al.
PLOS ONE (2012)
MYC and Aggressive B-cell Lymphomas
Graham W. Slack et al.
ADVANCES IN ANATOMIC PATHOLOGY (2011)
Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia
Melanie Bonnet et al.
BLOOD (2011)
Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1
Vanessa J. Craig et al.
BLOOD (2011)
Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas
Gustavo Tapia et al.
HISTOPATHOLOGY (2011)
Pathogenesis of diffuse large B cell lymphoma
Wing (John) C. Chan
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
Sharon Barrans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores
Alexandar Tzankov et al.
LEUKEMIA & LYMPHOMA (2010)
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Nathalie A. Johnson et al.
BLOOD (2009)
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
Kerry J. Savage et al.
BLOOD (2009)
Prognostic importance of BCL6 rearrangements in diffuse large B-cell lymphoma with respect to Bcl6 protein levels and primary lymphoma site
Alexandar Tzankov et al.
HUMAN PATHOLOGY (2009)
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
Maria Grazia Tibiletti et al.
HUMAN PATHOLOGY (2009)
Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
Christiane Copie-Bergman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma
E. C. Obermann et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment
E. C. Obermann et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge
E. G. Boerma et al.
LEUKEMIA (2009)
Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations
N. Niitsu et al.
LEUKEMIA (2009)
MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type
S. O. Yoon et al.
HISTOPATHOLOGY (2008)
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
Kai Fu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation
E. Leucci et al.
JOURNAL OF PATHOLOGY (2008)
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
W. Klapper et al.
LEUKEMIA (2008)
Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas
P. Bertrand et al.
LEUKEMIA (2008)
Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia
Birgit Kainz et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas
P. Bertrand et al.
LEUKEMIA (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma
Huan-You Wang et al.
CANCER GENETICS AND CYTOGENETICS (2007)
International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels
GA Gutman et al.
PHARMACOLOGICAL REVIEWS (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
EUROPEAN JOURNAL OF CANCER (2005)
Coexistent Rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma
C Ueda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
G Wright et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Genomic targets of the human c-Myc protein
PC Fernandez et al.
GENES & DEVELOPMENT (2003)
Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections
E Haralambieva et al.
JOURNAL OF PATHOLOGY (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
